A multicenter, multinational, randomised, double-blind, placebo-controlled, parallel-group, dose-finding study to investigate the anti-dyskinetic efficacy and safety of sarizotan in Parkinson patients with L-dopa-induced dyskinesia

Trial Profile

A multicenter, multinational, randomised, double-blind, placebo-controlled, parallel-group, dose-finding study to investigate the anti-dyskinetic efficacy and safety of sarizotan in Parkinson patients with L-dopa-induced dyskinesia

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Feb 2009

At a glance

  • Drugs Sarizotan (Primary)
  • Indications Drug-induced dyskinesia; Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors EMD Pharmaceuticals
  • Most Recent Events

    • 23 Feb 2009 EMD Serono reported as trial affiliate and sponsor by ClinicalTrials.gov.
    • 23 Feb 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov, last updated 23-2-2009.
    • 15 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top